Limited Effect of Intravenously Administered Indoxyl Sulfate, a Uremic Toxin, on the Hepatic Transport of Pravastatin in Normal Rats — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Limited Effect of Intravenously Administered Indoxyl Sulfate, a Uremic Toxin, on the Hepatic Transport of Pravastatin in Normal Rats
Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
,
Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
,
Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
,
Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
,
Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
,
Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
1 Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
2 Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
3 Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
4 Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
5 Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
6 Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
Indoxyl sulfate (IS) is a typical uremic toxin that extensively accumulates in the plasma of patients with seriously impaired renal function. This study s eeks to clarify whether IS exerts a potent modulating effect on the hepatic transport of pravastatin, which is a substrate of both organic anion transporting peptides (OATPs) and multidrug resistance-associated protein (Mrp) 2 in rats. When IS is administered intravenously to the normal rats at a dose of 120 μmol/kg ; plasma IS levels are approximately 600 μM after 2 min and 100 μM after 120 min. In rats with acute renal failure (ARF) induced by cisplatin, the area under the curve (AUC) was more than 2.5-fold greater compared with that in the normal rats, indicating that IS accumulates in ARF rats. Intravenously administered pravastatin almost disappeared from the plasma by 60 min post-administration and approximately 55% of dose was excreted in the bile within 60 min. This result suggested that pravastatin was efficiently taken up from the sinusoid into hepatocytes via rat OATPs on the sinusoidal membrane and preferentially transported in the bile mediated by Mrp2 on the canalicular membrane. IS administered intravenously at a dose of 120 μmol/kg caused neither an increase in plasma pravastatin levels nor a decrease in its biliary excretion. In conclusion, the present results demonstrate that single intravenous administration of IS does not interfere with the hepatic transport of pravastatin directly in vivo , which is at variance with the results of previous in vitro studies.
Vanholder, R., De Smet, R., Glorieux, G., Argilés, A., Baurmeister, U., Brunet, P., Clark, W., Cohen, G., De Deyn, P.P., Deppisch, R., Descamps-Latscha, B., Henle, T., Jörres, A., Lemke, H.D., Massy, Z.A., Passlick-Deetjen, J., Rodriguez, M., Stegmayr, B., Stenvinkel, P., Tetta, C., Wanner, C. and Zidek, W. (2003) Review on Uremic Toxins: Classification, Concentration, and Interindividual Variability. Kidney International, 63, 1934-1943. https://doi.org/10.1046/j.1523-1755.2003.00924.x
Leong, S.C. and Sirich, T.L. (2016) Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies. Toxins, 8, 358. https://doi.org/10.3390/toxins8120358
Hung, S.C., Kuo, K.L., Wu, C.C. and Tarng, D.C. (2017) Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. Journal of American Heart Association, 6, e005022. https://doi.org/10.1161/JAHA.116.005022
Taki, K., Nakamura, S., Miglinas, M., Enomoto, A. and Niwa, T. (2006) Accumulation of Indoxyl Sulfate in OAT1/3-Positive Tubular Cells in Kidneys of Patients with Chronic Renal Failure. Journal of Renal Nutrition, 16, 199-203. https://doi.org/10.1053/j.jrn.2006.04.020
Wu, W., Bush, K.T. and Nigam, S.K. (2017) Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in Vivo Handling of Uremic Toxins. Science Report, 7, Article No. 4939. https://doi.org/10.1038/s41598-017-04949-2
Tsutsumi, Y., Deguchi, T., Takano, M., Takadate, A., Lindup, W.E. and Otagiri, M. (2002) Renal Disposition of a Furan Dicarboxylic Acid and Other Uremic Toxins in the Rat. Journal of Pharmacology and Experimental Therapeutics, 303, 880-887. https://doi.org/10.1124/jpet.303.2.880
Nolin, T.D. (2008) Altered Nonrenal Drug Clearance on ESRD. Current Opinion in Nephrology and Hypertension, 17, 555-559. https://doi.org/10.1097/MNH.0b013e3283136732
Joy, M.S., Frye, R.F., Nolin, T., Roberts, B.V., La, M.K., Wang, J., Brouwer, K.L.R., Dooley, M.A. and Falk, R.J. (2014) In Vivo Alteration in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases. Pharmacotherapy, 34, 114-122. https://doi.org/10.1002/phar.1347
Yeung, C.K., Shen, D.D., Thummel, K.E. and Himmelfarb, J. (2014) Effects of Chronic Kidney Disease and Uremia on Hepatic Drug Metabolism and Transport. Kidney International, 85, 522-528. https://doi.org/10.1038/ki.2013.399
Reyes, M. and Benet, L.Z. (2011) Effects of Uremic Toxins on Transport and Metabolism of Different Biopharmaceutics Drug Disposition Classification System Xenobiotics. Journal of Pharmaceutical Sciences, 100, 3831-3842. https://doi.org/10.1002/jps.22640
Fujita, K., Sugiura, T., Okumura, H., Umeda, S., Nakamichi, N., Watanabe, Y., Suzuki, H., Sunakawa, Y., Shimada, K., Kawara, K., Sasaki, Y. and Kato, Y. (2014) Direct Inhibition and Down-Regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Human. Pharmaceutical Research, 31, 204-215. https://doi.org/10.1007/s11095-013-1153-x
Katsube, Y., Tsujimoto, M., Koide, H., Ochiai, M., Hojyo, A., Ogawa, K., Kambara, K., Torii, N., Shima, D., Furukubo, T., Izumi, S., Yamakawa, T., Minegami, T. and Nishiguchi, K. (2017) Cooperative Inhibitory Effects of Uremic Toxins and Other Serum Components on OATP1B1-Mediated Transport of SN-38. Cancer Chemotherapy and Pharmacology, 79, 783-789. https://doi.org/10.1007/s00280-017-3276-y
Sato, T., Yamaguchi, H., Kogawa, T., Abe, T. and Mano, N. (2014) Organic Anion Transporting Polypeptides 1B1 and 1B3 Play an Important Role in Uremic Toxin Handling and Drug-Uremic Toxin Interaction in the Liver. Journal of Pharmacy and Pharmaceutical Sciences, 17, 475-484. https://doi.org/10.18433/J3M89Q
Kalliokoski, A. and Niemi, M. (2009) Impact of OATP Transporters on Pharmacokinetics. British Journal of Pharmacology, 158, 693-705. https://doi.org/10.1111/j.1476-5381.2009.00430.x
Lin, C.J., Chen, H.H., Pan, C.F., Chuang, C.K., Wang, T.J., Sun, F.J. and Wu, C.J. (2011) p-Cresylsulfate and Indoxyl Sulfate Level at Different Stages of Chronic Kidney Disease. Journal of Clinical Laboratory Analysis, 25, 191-197. https://doi.org/10.1002/jcla.20456
Tan, X., Cao, X., Zou, J., Shen, B., Zhang, X., Liu, Z., Lv, W., Teng, J. and Ding, X. (2016) Indozyl Sulfate, a Valuable Marker in Chronic Kidney Disease and Dialysis. Hemodialysis International, 21, 161-167. https://doi.org/10.1111/hdi.12483
Everett, D.W., Chando, T.J., Didonado, G.C., Singhvi, S.M., Pan, H.Y. and Weinstein, S.H. (1991) Biotransformation of Pravastatin Sodium in Humans. Drug Metabolism and Disposition, 19, 740-748.
Deguchi, T., Kusuhara, H., Takadate, A., Endou, H., Otagiri, M. and Sugiyama, Y. (2004) Characterization of Uremic Toxin Transport by Organic Anion Transporters in the Kidney. Kidney International, 65, 162-174. https://doi.org/10.1111/j.1523-1755.2004.00354.x
Hua, W.J., Hua, W.X. and Fang, H.J. (2011) The Role of OATP1B1 and BCRP in Pharmacokinetics and DDI of Novel Statins. Cardiovascular Therapeutics, 30, e234-e241. https://doi.org/10.1111/j.1755-5922.2011.00290.x
Kellick, K. (2017) Organic Ion Transporters and Statin Drug Interactions. Current Atherosclerosis Report, 19, 65. https://doi.org/10.1007/s11883-017-0701-y
Ichimuta, Y., Takamatsu, H., Ideuchi, H., Takeda, K. and Saitoh, H. (2015) Plasma Concentrations of Anionic Uremic Toxins in Hemodialysis Patients and Their Effects on Protein Binding of Pravastatin. Yakugaku Zasshi, 135, 821-828.
Ichimuta, Y., Takamatsu, H., Ideuchi, H., Takeda, K. and Saitoh, H. (2016) Correlations between Plasma Levels of Anionic Uremic Toxins and Clinical Parameters in Hemodialysis Patients. Yakugaku Zasshi, 136, 1177-1184. https://doi.org/10.1248/yakushi.15-00252
Ellis, L.C., Hawksworth, G.M. and Weaver, R.J. (2013) ATP-Dependent Transport of Statins by Human and Rat MRP2/Mrp2. Toxicology and Applied Pharmacology, 269, 187-194. https://doi.org/10.1016/j.taap.2013.03.019
Ieiri, I., Higuchi, S. and Sugiyama, Y. (2009) Genetic Polymorphisms of Uptake (OATP1B1, 1B3) and Efflux (MRP2, BCRP) Transporters: Implications for Inter-Individual Differences in the Pharmacokinetics and Pharmacodynamics of Statins and Other Clinically Relevant Drugs. Expert Opinion on Drug Metabolism and Toxicology, 5, 703-729. https://doi.org/10.1517/17425250902976854
Tsujimoto, M., Hatozaki, D., Shima, D., Yokota, H., Furukubo, T., Izumi, S., Yamakawa, T., Minegaki, T. and Nishiguchi, K. (2012) Influence of Serum in Hemodialysis Patients on the Expression of Intestinal and Hepatic Transporters for the Excretion of Pravastatin. Therapeutic Apheresis and Dialysis, 16, 580-587. https://doi.org/10.1111/j.1744-9987.2012.01100.x